The Mandel Center for Hypertension and Atherosclerosis at Duke Cardiovascular Research Center has awarded Duke Anesthesiology’s Satya Achanta, DVM, PhD, a one-year, $47,736 seed grant for his project, titled “Exosomes Prevent Remodeling of Ventricles and Improve Cardiac Function in Myocardial Infarction in a Human Translational Model of Pigs.” Dr. Achanta is a member of the Chemical Sensing, Pain and Inflammation Research Laboratory, led by Dr. Sven-Eric Jordt.
Myocardial infarction (MI, heart attack) is the most common cause of congestive heart failure and death. The rupture of atherosclerotic plaque (wax-like build up) with subsequent thrombus formation in coronary arteries is the common cause of MI. Acute in-hospital MI is treated with reperfusion strategies coupled with anticoagulation and vasodilation therapies. However, the mortality rate is still high in patients who have adverse ventricular remodeling. Therefore, there has been a continuous need for an effective therapy. In this application, Dr. Achanta investigates the use of regenerative exosomes derived from donor heart tissue or blood samples as a novel treatment for restoring the function and architecture of the heart in a pig model of human translational MI.
Collaborators on this grant include Dr. Ke Cheng of NC State University, Drs. Ray Kim, Han Kim, and David Wendell of Duke MRI Cardiology, and Dr. Richard Krasuski of Duke Medicine-Cardiology. Dr. Achanta developed and optimized dog models of myocardial infarction using two approaches, ischemia/reperfusion through a lateral thoracotomy and microsphere injection into coronary arteries under fluoroscopy, in collaboration with Dr. Kim’s lab (Duke Cardiac MRI Laboratory). This work successfully reproduced dog models of MI with consistent cardiac MRI and histopathology outcomes.